drugset
drugset / Trial / NCT01684761

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

NCT01684761 ↗

Phase 2 Completed 183 enrolled Opexa Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Tcelna (imilecleucel-T, autologous T-Cell Immunotherapy) is effective in the treatment of secondary progressive multiple sclerosis (SPMS).

Timeline

Start
2012-08
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject imilecleucel-T Cell therapy 3e+07 cells Subcutaneous

Indications

secondary progressive multiple sclerosis